Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Anticholinergics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    92 result(s) found for: Anticholinergics. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2006-005557-30 Sponsor Protocol Number: FB/PS/14/165/06 Start Date*: 2007-03-16
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: In-vivo deposition measurement of formoterol and beclomethasone after inhalation of a single dose of the combination Formoterol plus BDP HFA pMDI (Foster®, Chiesi) in healthy volunteers, asthmatic...
    Medical condition: The study is focused on asthma bronchiale and chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003872-20 Sponsor Protocol Number: 07-LICFOR-01 Start Date*: 2007-11-08
    Sponsor Name:Laboratorios Liconsa S.A.
    Full Title: A RANDOMISED, DOUBLE-BLIND, SINGLE-DOSE, TWO-WAY CROSSOVER STUDY TO ASSESS THE BRONCHODILATING PROPERTIES OF A NEW GENERIC DRY POWDER FORMOTEROL FORMULATION GIVEN FROM A NOVEL DRY POWDER INHALER CO...
    Medical condition: This study has been initianed to assess the bronchodilating properties of a new generic dry powder formoterol formulation given from a novel dry powder inhaler compared to the reference Foradil Aer...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000957-30 Sponsor Protocol Number: 191622-117 Start Date*: 2012-08-28
    Sponsor Name:Allergan Ltd.
    Full Title: BOTOX® for the Treatment of Urinary Incontinence due to Neurogenic Detrusor Overactivity in Patients with Multiple Sclerosis
    Medical condition: Urinary incontinence due to neurogenic detrusor overactivity (NDO) resulting from multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002999-34 Sponsor Protocol Number: Y-79-52120-126 Start Date*: 2007-12-04
    Sponsor Name:Ipsen Limited
    Full Title: A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one ...
    Medical condition: Idiopathic overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020853 Hypertonic bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) BE (Completed) FR (Completed) CZ (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002308-32 Sponsor Protocol Number: P04229 Start Date*: 2007-05-16
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Randomized Placebo-Controlled Efficacy and Safety Study of 1-Year Duration with High and Medium Dose Inhaled Mometasone Furoate/Formoterol Combination Formulation Compared With Formoterol and Hig...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) SK (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-005015-28 Sponsor Protocol Number: 1289.6 Start Date*: 2014-10-31
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of four orally administrated doses of BI 409306 during a 12-week treatment perio...
    Medical condition: Patients with schizophrenia on stable antispychotic treatment
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10039634 Schizophrenia residual LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005295-33 Sponsor Protocol Number: S54913 Start Date*: 2013-03-08
    Sponsor Name:UZ Leuven-Department of Urology
    Full Title: Monocentric, open-label, phase III study that compares the efficiency and tolerance between intravesical oxybutynin and oral fesoterodine in children (5-16y) with neurogenic detrusor overactivity.
    Medical condition: children with neurogenic detrusor overactivity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10041524 Spina bifida PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002309-30 Sponsor Protocol Number: P04230 Start Date*: 2007-06-18
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Randomized Placebo-Controlled Efficacy and Safety Study of 1-Year Duration with High and Medium Dose Inhaled Mometasone Furoate/Formoterol Combination Formulation Compared With Formoterol and Hig...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) HU (Completed) SK (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004877-26 Sponsor Protocol Number: 191622-120 Start Date*: 2013-07-18
    Sponsor Name:Allergan Ltd.
    Full Title: BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age
    Medical condition: Urinary Incontinence Due to Neurogenic Detrusor Overactivity
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) AT (Completed) IT (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-009096-35 Sponsor Protocol Number: QGUY/2008/TA-270/-01 Start Date*: 2009-03-12
    Sponsor Name:Activus Pharma Co., Ltd
    Full Title: An open-label, 28-day multiple dose pilot study to evaluate the effects on lung oxidative stress, safety and pharmacokinetics of TA-270 in patients with chronic obstructive pulmonary disease (COPD).
    Medical condition: Chronic obstructive pulmonary disease. ( COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002740-82 Sponsor Protocol Number: 1346-0038 Start Date*: 2019-03-07
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 wee...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10039632 Schizophrenia NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-003949-28 Sponsor Protocol Number: Inco_Ona1 Start Date*: 2018-08-07
    Sponsor Name:PROF. ANTONELLA GIANNANTONI - CLINICA UROLOGICA - UNIVERSITà DI PERUGIA
    Full Title: Incobotulinumtoxin versus Onabotulinumtoxin in the treatment of patients with overactive bladder syndrome
    Medical condition: neurogenic overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10032081 Other functional disorder of bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000129-76 Sponsor Protocol Number: BTXSENS Start Date*: 2007-04-27
    Sponsor Name:Guy's & St Thomas' NHS Foundation Trust
    Full Title: Botulinum toxin-A in Sensory Urgency
    Medical condition: Sensory Urinary Urgency. This is a condition where patients have urinary urgency (sudden desire to urinate which cannot be deferred) /- urge incontinence (urine leakage) and usually is accompanied ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000711-24 Sponsor Protocol Number: 2013-000711-24 Start Date*: 2013-10-09
    Sponsor Name:Søren Rittig
    Full Title: The effect of combining anticholinergic treatment and transcutaneous electrical nerve stimulation in children suffering from daytime urinary incontinence and an overactive bladder.
    Medical condition: Daytime urinary incontinence and overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000253-21 Sponsor Protocol Number: 106538 Start Date*: 2006-04-12
    Sponsor Name:GlaxoSmithKline GmbH & Co KG
    Full Title: Reaching asthma control with salmeterol/fluticasone 50 / 250µg bd combination in steroid naive or low dose JCS patients by using the asthma control test (ACT) as measurement.
    Medical condition: Asthma control
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003597-25 Sponsor Protocol Number: SCO107227 Start Date*: 2007-10-08
    Sponsor Name:GlaxoSmithKline GmbH & Co. KG
    Full Title: A 12-month open-label, randomized parallel-group study to investigate the influence of salmeterol/fluticasone either in fixed combination (SFC500/50 µg bid) or seperately (SAL 50 µg and FP 500 µg b...
    Medical condition: Severe and very severe COPD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003410-18 Sponsor Protocol Number: MRZ 60201-0605/1 Start Date*: 2007-09-07
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, single-arm, multicenter trial to investigate the efficacy and safety of NT 201 (botulinum neurotoxin type A free of complexing proteins) and the duration of treatment effect after one ...
    Medical condition: Cervical dystonia, predominantly rotational spasmodic torticollis
    Disease: Version SOC Term Classification Code Term Level
    10.0 10064124 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000697-23 Sponsor Protocol Number: MRZ 60201-0703/1 Start Date*: 2007-07-10
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, single-arm, single-center, open-label trial to investigate the tolerability of NT 201 and quality of life of patients in the treatment of blepharospasm with shortened injection intervals
    Medical condition: Blepharospasm
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005159 Blepharospasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004296-22 Sponsor Protocol Number: 2014-RdC-PRO-Th Start Date*: 2015-11-10
    Sponsor Name:Centre Eugène Marquis
    Full Title: Anticholinergics impact in the treatment of acute irritative urinary toxicity during radiotherapy for prostate cancer
    Medical condition: Symptomatology related to acute urinary toxicity occuring during prostate irradiation in patients suffering from prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004857 10004995 Bladder and urethral symptoms HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002877-23 Sponsor Protocol Number: 1.0 Start Date*: 2019-01-21
    Sponsor Name:Abteilung für Neurologie der Medizinischen Universität Innsbruck
    Full Title: Oxytocin and social attention in healthy controls and patients with Parkinson's disease. A randomised, double-blind, placebo-controlled, crossover eye tracking study.
    Medical condition: Social functioning in Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 19:53:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA